- Vertex Pharmaceuticals ( NASDAQ: VRTX ) and Verve Therapeutics ( NASDAQ: VERV ) will collaborate on developing a gene editing program for a liver disease .
- Under the four-year arrangement, Verve ( VERV ) will be responsible for discovery, research and certain preclinical development of a novel in vivo gene editing program for a target. Vertex will pay for these program costs and also handle further development, manufacturing and commercialization of any program from Verve's ( VERV ) research.
- Verve ( VERV ) will receive a $60M upfront payment that includes a $35M equity investment. Verve is also eligible for up to $66M in success payments, up to $340M in milestones, and tiered royalties on future net sales.
- Verve shares are down 16% in post-market trading after announcing a $200M underwritten stock offering .
For further details see:
Vertex, Verve in gene editing partnership for liver disease worth up to $466M